Automatic Volume Assessment Tool
Monitor patient outcomes pre- and post-surgery with automated volume assessment
Company profile
Company profile
Cydar Medical is a medical technology company founded in 2014 that specializes in transforming minimally invasive image-guided surgery through artificial intelligence and advanced imaging solutions. The company's flagship product, Cydar Maps, is a comprehensive Software-as-a-Medical Device (SaMD) platform that supports the entire surgical workflow—from pre-operative planning to intraoperative guidance and post-operative analysis. The Cydar Image Guided Surgery Platform (CIGSP) leverages cloud-based AI technology and data fusion to empower clinical teams with actionable insights for faster, easier, and more informed surgical decisions. The platform creates 3D surgical plans using AI-enhanced vessel measurements, provides real-time intraoperative guidance with surgical precision, and enables automatic volume assessment for monitoring patient outcomes. Clinical evidence demonstrates significant improvements including reductions in radiation exposure, procedure times, and contrast agent use. Cydar Medical serves healthcare providers including hospitals, health systems, and vascular surgery departments primarily in the United States, United Kingdom, and European Union. The platform is designed for complex endovascular aortic procedures and other image-guided minimally invasive surgeries. The company's technology integrates seamlessly with existing hospital systems including PACS and operating room displays, while maintaining GDPR and HIPAA compliance. Cydar also partners with innovative software companies to accelerate the deployment of AI applications in surgical settings, providing a centralized framework that simplifies procurement, implementation, and ongoing support for healthcare institutions.
Company description Cydar official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Cloud Saas · Hybrid deployment with recorded integration context.
Recorded integration context: Imaging systems, Operating room displays, PACS.
Company milestones
Expansion of Cydar Maps solution for greater efficiency (2025), ongoing deployment across major healthcare systems
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
Monitor patient outcomes pre- and post-surgery with automated volume assessment
iOS and Android app for secure photo sharing and 24/7 support access
Platform connecting operating rooms and cloud for Software-as-a-Medical Device applications
AI-powered 3D surgical planning and guidance platform for minimally invasive image-guided surgery
Guiding your procedure with surgical precision during surgery
Create 3D surgical plans leveraging AI enhanced vessel measurements and insights
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Trials · Apr 30, 2025
The ARIA trial protocol: a randomised controlled trial to assess the clinical, technical, and cost-effectiveness of a cloud-based, ARtificially Intelligent image fusion system in comparison to standard treatment to guide endovascular Aortic aneurysm repair.Trials · Mar 25, 2024
Accuracy of implementing principles of fusion imaging in the follow up and surveillance of complex aneurysm repair.Vascular medicine (London, England) · Oct 1, 2018
Clinical validation
NCT06590532 · Mentioned · RECRUITING
Patient and Staff Safety During Aorto-iliac Revascularization Procedures Under Automated Fusion Imaging Guidance With ControlsNCT03713450 · Mentioned · TERMINATED
A Case Control Observational Study to Assess CYDAR Automated Overlay Guidance During EVARNCT02592733 · Mentioned · COMPLETED
Regulatory
K212442 · 510k · Dec 3, 2021
Cydar EVK160088 · 510k · Jul 7, 2016
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Percentage reduction during procedures
Percentage reduction in surgical duration
Percentage reduction in contrast media
Better surgical planning and procedure execution for vascular surgery cases
Surgeon will not operate without the planning software
Managing complex anatomy in vascular surgery and endovascular therapy
Tremendous impact in operating room environment for complex anatomy cases
Growing complex EVAR program and improving surgical outcomes
Demonstrated value in reducing radiation, contrast, and procedure time; improved confidence in device positioning and simplified branch cannulation
05 · Leadership
Leadership profiles and professional links from the current Company record.
Paul Mussenden
Chief Executive Officer
Graeme Penney
Chief Scientific Officer & Co-Founder
Vanisha Mistry
VP of Operations
Emma Walters
VP of People
Rob Hague
Chief Software Architect
Kenneth Hitchner
Chairman of the Board
Edward Carrell
Company Director
Andrew Wolfsman
Pembroke Investment Director
06 · Company updates
Recent articles published on Cydar's official website.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.